An American study shows that levofloxacin is more cost-effective than moxifloxacin for outpatient CAP treatment
Hospital admissions account for a great deal of the medical costs associated with community-acquired pneumonia (CAP) which is initially treated in an outpatient setting and current CAP treatment guidelines do not distinguish between outpatient treatment with levofloxacin and moxifloxacin. Staff at the Analysis Group, Inc., Boston, USA, have compared the healthcare resource use and medical costs associated with episodes of CAP in the PharMetrics database over the period 2004 to 2007. This identified a total of 15,472 levofloxacin- and 6474-moxifloxacin treated CAP patients. A total of 6352 matched pairs were obtained and their case details were analyzed. It emerged that outpatients started on levofloxacin produced substantially lower costs to payers compared with patients started on moxifloxacin. The difference was mainly due to reduced rates of pneumonia-related admission to hospital or ER visits.
Curr Med Res Opin. 2009 Dec 9. [Epub ahead of print]
Source : http://www.ncbi.nlm.nih.gov/pubmed/19995325?dopt=Abstract